Preview Newsletter
XARELTO Media Monitoring – Week of 4-22-16
-
Pradaxa Lawsuit Results Provide Encouragement For Plaintiffs In Current Xarelto Lawsuits
Apr 18, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on substantial similarities noted between Xarelto and Pradaxa lawsuits, which now help to give current Xarelto lawsuit plaintiffs encouragement as they await scheduled 2017 bellwether trials. Xarelto lawsuit filings are still increasing in number regularly. Those which were federally-filed have been transferred to a single court and consolidated by the U.S. Judicial Panel on Multidistrict Litigation, forming MDL number 2592. These cases are reported to number over 2,800 today. Additionally, another grouping of over 600 lawsuits referencing Xarelto have been consolidated to form a mass tort program by the Court of Common Pleas in Philadelphia, Pennsylvania. -
Nebraska Xarelto Lawsuit Plaintiffs Allege Drug Caused Serious And Permanent Damage
Apr 19, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on another lawsuit which has been filed against Janssen Pharmaceuticals (a division of Johnson & Johnson) and manufacturer of new-generation blood thinner Xarelto. This particular complaint was filed in Eastern Louisiana under case number 2:15-cv-06514. It was filed by a couple from Nebraska who allege that Janssen marketed a dangerous blood thinner which caused the husband certain serious and lasting side effects including internal bleeding events and a decreased life expectancy. -
Miami New Times Discusses Potential Dangers Highlighted In Xarelto Lawsuits
Apr 19, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on a recent news release from the Miami New Times which discusses the thousands of patients who are now suing the manufacturers of new-generation blood-thinning drug Xarelto. The news source makes note of the fact that this blood thinner is advertised by the Miami Heat’s Chris Bosh. -
Xarelto Lawsuit Allegations Question Anticoagulant’s Rare One-Pill-Per-Day Dosage
Apr 20, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on the details of one of the thousands of lawsuits which has been filed against Xarelto manufacturers Janssen Pharmaceuticals (a subdivision of Johnson & Johnson) and Bayer AG. This lawsuit is especially notable as its allegations differ from most of the rest. It was filed in a Pennsylvania State Court. Most of the thousands of Xarelto lawsuit complaints that currently exist were filed against the same defendants but instead referenced the anticoagulant’s alleged sudden bleeding episode dangers. However, this lawsuit brings up another concern: the drug’s one-pill-per-day, one-dose-for-all instructions. -
Xarelto Lawsuit Plaintiff Requests $4.35 Million Compensation After Suffering Alleged Uncontrollable Bleeding Episode
Apr 20, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on a lawsuit which was filed against Bayer AG and Janssen Pharmaceuticals (a division of corporate giant Johnson & Johnson), as well as several other defendants, in reference to the blood-thinning drug Xarelto. The plaintiff filing this complaint alleges that Xarelto caused him to suffer from an unexpected and dangerous bleeding episode. -
Xarelto Lawsuit Plaintiff Requests $4.35 Million Compensation After Suffering Alleged Uncontrollable Bleeding Episode
Apr 20, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on a lawsuit which was filed against Bayer AG and Janssen Pharmaceuticals (a division of corporate giant Johnson & Johnson), as well as several other defendants, in reference to the blood-thinning drug Xarelto. The plaintiff filing this complaint alleges that Xarelto caused him to suffer from an unexpected and dangerous bleeding episode. -
Combined Xarelto Lawsuit Numbers Surpass 3,400 In Louisiana MDL And Philadelphia Mass Tort Program
Apr 20, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on recently reported Xarelto lawsuit numbers, which show that complaints filed in reference to Xarelto against defendants Bayer AG and Janssen Pharmaceuticals (a division of Johnson & Johnson) have now surpassed 3,400 in number across the United States. This mounting number is made up of two main large groupings of lawsuits: a consolidation of over 2,800 Xarelto lawsuits which were transferred to a single court in Eastern Louisiana by the U.S. Judicial Panel on Multidistrict Litigation, forming MDL number 2592, as well as a mass tort program made up of over 620 lawsuits which was consolidated in Philadelphia, Pennsylvania by the Court of Common Pleas. -
Xarelto Lawsuit Numbers Surpass 3,400 Filings In Louisiana And Pennsylvania Within 5 Years
Apr 21, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on Xarelto lawsuit filings which have surpassed 3,400 in number over the last 5 years alone. Xarelto is a new-generation anticoagulant which gained approval from the U.S. Food and Drug Administration in 2011. When the anticoagulant was first released to market, it was very popular and has reportedly brought in billions of dollars for manufacturers Bayer AG and Janssen Pharmaceuticals (a division of Johnson & Johnson). The blood thinner was FDA approved to treat patients who were recovering from knee and hip replacement surgeries, as well as those suffering from deep vein thrombosis, pulmonary embolism, or atrial fibrillation by preventing the risk of blood clots and strokes. -
Xarelto Lawsuit Plaintiffs Await Results From Investigation Of European Regulators Into Xarelto Clinical Trials
Apr 21, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
BloodThinnerHelp.com comments on details of an investigation which is reportedly being conducted by European regulators in reference to clinical trial results conducted on Xarelto. The investigation is coming at a time when a surge of Xarelto-related lawsuits have been filed against Bayer AG and Janssen Pharmaceuticals (a division of Johnson & Johnson). Thousands of lawsuits have been filed against the blood-thinning drug by plaintiffs who similarly allege that use of the drug can place patients at heightened risk for sudden, dangerous bleeding episodes. -
Xarelto Lawsuit Allegations Question Anticoagulants Rare One-Pill-Per-Day Dosage
Apr 22, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on the details of one of the thousands of lawsuits which has been filed against Xarelto manufacturers Janssen Pharmaceuticals (a subdivision of Johnson & Johnson) and Bayer AG. This lawsuit is especially notable as its allegations differ from most of the rest. It was filed in a Pennsylvania State Court. Most of the thousands of Xarelto lawsuit complaints that currently exist were filed against the same defendants but instead referenced the anticoagulant’s alleged sudden bleeding episode dangers. However, this lawsuit brings up another concern: the drug’s one-pill-per-day, one-dose-for-all instructions. -
Xarelto Lawsuit Filings Reportedly Increasing In United States And Canada
Apr 22, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on Xarelto bleeding lawsuits, which have been steadily increasing in number in the United States, and in Canada as well. It was reported that a Xarelto related lawsuit was filed last February in Calgary, Canada and that another is expected to be filed in Ontario. To involved plaintiffs in the United States, this is proof that Canadian patients have struggled with bleeding risks and the lack of a ready antidote while using the drug as well. -
Nebraska Xarelto Lawsuit Plaintiffs Allege Drug Caused Serious And Permanent Damage
Apr 21, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on another lawsuit which has been filed against Janssen Pharmaceuticals (a division of Johnson & Johnson) and manufacturer of new-generation blood thinner Xarelto. This particular complaint was filed in Eastern Louisiana under case number 2:15-cv-06514. It was filed by a couple from Nebraska who allege that Janssen marketed a dangerous blood thinner which caused the husband certain serious and lasting side effects including internal bleeding events and a decreased life expectancy. -
Xarelto
Apr 17, 2016 | NastLaw LLC
Xarelto is a widely prescribed blood thinning medication that can cause serious and irreversible bleeding. Xarelto has been linked to numerous deaths since it was approved in 2011. Individuals who were taking Xarelto and were hospitalized due to severe bleeding may be eligible for a lawsuit against the manufacturers of Xarelto. -
Xarelto uncontrolled bleeding trigger lawsuits
Apr 20, 2016 | The Legal Examiner
By Shezad Malik
Lawsuits filed against the makers of Xarelto have surpassed 4,500 since the drug was approved by the U.S. Food and Drug Administration (FDA) in 2011. -
Xarelto
| Heygood, Orr & Pearson
Thousands of lawsuits have been filed by patients who suffered severe bleeding linked to the bloodthinner Xarelto. Hundreds of deaths and thousands of cases of severe bleeding incidents or other adverse events have been reported by patients who were prescribed Xarelto to prevent blood clots. -
Xarelto MDL Lawsuits Top 4,500 Cases Involving Bleeding Injuries
Apr 20, 2016 | AboutLawsuits.com
By Joseph Osborne
As parties involved in the federal Xarelto bleeding injury lawsuits are scheduled to meet today with the judge presiding over the coordinated pretrial proceedings, a new report suggests that the total number of cases pending in the federal multidistrict litigation (MDL) has recently topped 4,500. -
Canadian Xarelto Class Action Lawsuit Filed
Apr 21, 2016 | BigClassAction.com
Bayer Inc, is facing a Xarelto class-action lawsuit filed in Calgary alleging its blood thinner is linked to dozens of deaths. The lead plaintiff in this class action alleges that the anticoagulant drug caused her to suffer from an uncontrollable bleeding event which nearly led her to cardiac arrest. -
Court Chooses 40 Xarelto Lawsuits for Bellwether Trial
Apr 21, 2016 | Top Class Actions
By Joanna Szabo
All federally filed Xarelto lawsuits were consolidated into one multidistrict litigation, or MDL, on Dec. 12, 2014 in the Eastern District of Louisiana, and potential cases for early bellwether trials have been reviewed since the MDL consolidation. -
Xarelto Users Scrutinize TV Ads After Suffering Injuries
Apr 21, 2016 | Meyerkord & Meyerkord LLC
Retired NBA player, Chris Bosh, comedian, Kevin Nealon, golfer, Arnold Palmer, and Nascar driver, Kevin Vickers, are all featured in several television commercials advertising the blood thinner Xarelto. In the commercials, they praise the drug and promote it as being the best choice for individuals needing a blood thinner. The main focus in the commercials is that Xarelto is the most convenient option compared to other blood thinners. Warfarin, a coagulant that has been on the market for several years, requires users to undergo regular blood tests and alter their diets. Xarelto does not require any changes to the users lifestyle. Many Xarelto users are angry after witnessing the advertisements claiming they were injured as a result of the drug.
Client Attorney Privileged/Attorney Work Product/At Request of Counsel
Full Text of Stories Below
Plaintiff Attorney Press Releases
Plaintiff Attorney Blog Posts
-
Pradaxa Lawsuit Results Provide Encouragement For Plaintiffs In Current Xarelto Lawsuits
Apr 18, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on substantial similarities noted between Xarelto andPradaxa lawsuits, which now help to give current Xarelto lawsuit plaintiffs encouragement as they await scheduled 2017 bellwether trials. Xarelto lawsuit filings are still increasing in number regularly. Those which were federally-filed have been transferred to a single court and consolidated by the U.S. Judicial Panel on Multidistrict Litigation, forming MDL number 2592. These cases are reported to number over 2,800 today. Additionally, another grouping of over 600 lawsuits referencing Xarelto have been consolidated to form a mass tort program by the Court of Common Pleas in Philadelphia, Pennsylvania.
Lawsuits which have become a part of the MDL are housed in Eastern Louisiana and are being overseen by Judge Eldon Fallon. The involved complaints have been filed against defendants Bayer AG and Johnson & Johnson subsidiary, Janssen Pharmaceuticals. In addition, involved plaintiffs share strikingly similar allegations that use of the new-generation blood thinner puts patients at increased risk for severe and potentially life-threatening bleeding episodes.
Just five years ago, in 2011, Xarelto was released to market without any corresponding antidote. This was a point of contention for many over the next several years, as allegations brought attention to the dangers that a lack of antidote could pose for anyone injured while on blood thinners. Although Xarelto was approved by the U.S. Food and Drug Administration, it also received two “black box” warnings from the agency, which are the most severe warnings possible for the FDA to give a product. Xarelto was approved to treat patients recovering from knee and hip replacement surgeries, as well as those suffering from deep vein thrombosis, pulmonary embolism, or atrial fibrillation condition.
Pradaxa is similar to Xarelto in that it is also considered to be a new-generation anticoagulant. It was marketed by Boehringer Ingelheim in October of 2010. As has occurred with Xarelto, the blood thinner quickly became the topic of over 3,500 adverse event reports and later more than 4,000 lawsuits involving similar allegations. The plaintiffs involved in these lawsuits, as Xarelto plaintiffs are today, were anxiously awaiting their trial dates. The evening before the trial was set to begin, however, the defendant decided to settle the lawsuits and paid $650 million to plaintiffs.
Today, Xarelto lawsuit plaintiffs find some comfort in this outcome, as they look to attain what they consider to be some sort of justice. There have been no reported discussions of settlement talks for Xarelto lawsuits at this time, but new controversies have recently emerged surrounding the clinical trials of the drug, which lead some involved parties to believe that settlement is becoming more likely.
As those involved continue to await trial, Attorney Joseph Osborne is hoping to help ensure that other patients who have used Xarelto and who feel that it caused them to suffer from adverse health events will be given the important opportunity to explore their legal rights in the matter. Affected patients could be entitled to legal action and significant compensation. To better assist those wanting to learn more, Attorney Osborne is offering complimentary legal consultations for affected individuals at this time.
To ask questions regarding Xarelto bleeding lawsuits, or to request additional information, please contact Attorney Joseph Osborne by calling (866) 425-8902.
http://www.digitaljournal.com/pr/2906564
-
Nebraska Xarelto Lawsuit Plaintiffs Allege Drug Caused Serious And Permanent Damage
Apr 19, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on another lawsuit which has been filed against Janssen Pharmaceuticals (a division of Johnson & Johnson) and manufacturer of new-generation blood thinner Xarelto. This particular complaint was filed in Eastern Louisiana under case number 2:15-cv-06514. It was filed by a couple from Nebraska who allege that Janssen marketed a dangerous blood thinner which caused the husband certain serious and lasting side effects including internal bleeding events and a decreased life expectancy.
It was reported that the husband was prescribed Xarelto and used it May 2013 through December 2013. In December, he suffered from a sudden gastrointestinal bleeding episode. The plaintiffs allege that this event was caused by Xarelto, and are requesting compensatory and punitive damages at this time.
Many plaintiffs from across the United States have stepped forward alleging much the same. Xarelto has in fact become the subject of over 3,400 lawsuits filed within the last 5 years alone, by plaintiffs who commonly claim that the anticoagulant places users at heightened risk for a variety of negative side effects, but most commonly bleeding events. Lawsuits which have been federally-filed were transferred and consolidated to a single court in Eastern Louisiana by the U.S. Judicial Panel on Multidistrict Litigation, forming MDL No. 2592. These complaints currently number over 2,800, and are joined by over 620 others in Philadelphia, Pennsylvania which were formed into a mass tort program by the Court of Common Pleas.
Plaintiffs involved in these lawsuit groupings are anxiously awaiting trial dates as new controversies surrounding the clinical trials of Xarelto and FDA approval of the drug have surfaced. Attorney Joseph Osborne believes that other lawsuits will continue to be filed in the meantime, and is currently working to help other patients who have taken Xarelto and who have suffered from adverse health events that they believe were caused by the blood thinner. Affected patients may be entitled to substantial compensation, and deserve the opportunity to explore their legal rights in the matter fully. To better assist those interested in learning more about their options, Attorney Osborne is currently offering free legal consultations to qualified individuals.
To request further Xarelto lawsuit information, or to ask questions, please contact Joseph Osborne, Esq. by calling (866) 425-8902.
http://www.digitaljournal.com/pr/2908368
-
Miami New Times Discusses Potential Dangers Highlighted In Xarelto Lawsuits
Apr 19, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on a recent news release from the Miami New Timeswhich discusses the thousands of patients who are now suing the manufacturers of new-generation blood-thinning drug Xarelto. The news source makes note of the fact that this blood thinner is advertised by the Miami Heat’s Chris Bosh.
In one of these advertisements, according to Miami New Times, Bosh is seen sinking a 3-point shot in a dark gym, when he solemnly states, “When I was sidelined with blood clots in my lungs, it was serious…” he then notes, “Fortunately, my doctor had a game plan.”
Bosh has reportedly suffered from blood clot related health problems, which have in fact sidelined the all-star basketball player. The advertisements from Xarelto go on to indicate that the anticoagulant drug was the “right choice” for him. Xarelto has made billions for manufacturers Bayer AG and Janssen Pharmaceuticals, (a division of Johnson & Johnson corporation). Many plaintiffs who have referenced the drug in lawsuits today, however, indicate that these advertisements are misleading, and do not accurately depict the dangers surrounding Xarelto use.
Today, Xarelto has become the topic of over 3,400 lawsuits filed by plaintiffs from across the nation. These lawsuits have been formed into two major groupings. Over 2,800 of them have been transferred to a single court and consolidated by the U.S. Judicial Panel on Multidistrict Litigation forming MDL 2592 in Eastern Louisiana, while another group of more than 620 lawsuits has been consolidated to form a mass tort program by the Court of Common Pleas in Philadelphia, Pennsylvania.
These thousands of plaintiffs commonly agree that Xarelto is not the “right move” for them. The news article discusses the case of a 37-year-old woman from South Florida who is employed as a medical technician. The woman says that she suffered terrifying blood loss while using Xarelto. She is quoted as saying, “I’ve seen that commercial with Bosh and the other guys, and it’s full of crap.” And also, “I just shake my head seeing them pushing this drug.”
The woman explains that while she was taking Xarelto, the drug had no available antidote for bleeding situations. She says that she was prescribed the blood thinner to treat an irregular heartbeat, but when she got her next period, she started to bleed much more heavily. In a short time, she states that she became so weak she was unable to walk. She was rushed to the emergency room and required a two-pint blood transfusion. “I could have bled to death,” she noted. “Thank God it was just my period and it wasn’t a head injury or something.”
The article also quotes Attorney Joseph Osborne, who practices law in Boca Raton and who is currently working to help others who have used Xarelto and have suffered from health complications that they believe were caused by the drug. Attorney Osborne is working to help ensure that everyone who feels they have been negatively affected by the drug will be given a chance to fully evaluate their legal rights in the matter. These patients could be entitled to significant compensation attained through legal action. To better assist those wishing to investigate their legal options, Attorney Osborne is also now offering free legal consultations for qualified parties.
To request additional information on Xarelto bleeding lawsuits, or to ask questions, please contact Joseph Osborne, Esq. by calling (866) 425-8902.
http://www.digitaljournal.com/pr/2907936
-
Xarelto Lawsuit Allegations Question Anticoagulant’s Rare One-Pill-Per-Day Dosage
Apr 20, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on the details of one of the thousands of lawsuits which has been filed against Xarelto manufacturers Janssen Pharmaceuticals (a subdivision of Johnson & Johnson) and Bayer AG. This lawsuit is especially notable as its allegations differ from most of the rest. It was filed in a Pennsylvania State Court. Most of the thousands of Xarelto lawsuit complaints that currently exist were filed against the same defendants but instead referenced the anticoagulant’s alleged sudden bleeding episode dangers. However, this lawsuit brings up another concern: the drug’s one-pill-per-day, one-dose-for-all instructions.
Out of many blood thinners, Xarelto is the only one to offer a single pill dose. Most blood-thinning drugs instruct that users take 2 pills each day to properly ensure they will remain medicated for a full 24-hours. This plaintiff’s lawsuit indicates that this recommended once-daily dosage is ineffective in protecting patients for a full day. The plaintiff alleged this after unexpectedly suffering from a stroke just four days after beginning to use Xarelto in order to prevent strokes, which he was deemed to be at heightened risk for due to a heart condition called atrial fibrillation.
Atrial fibrillation is a fairly common heart condition which can cause patient’s heart rates to be faster than normal. This can put patients at increased risk of stroke, and therefore, patients with this condition have been approved for treatment with blood thinners. After suffering a stroke, the plaintiff filed his lawsuit in Pennsylvania on October 8, 2015. As the first lawsuit of its kind, his allegations have drawn increased public attention and have raised new concerns regarding use of the drug. In addition to claiming that the blood thinner failed to prevent his stroke, the plaintiff has alleged that the drug may have actually caused it.
After approval by the U.S. Food and Drug Administration in 2011, Xarelto was released to the market for public sale and thought of as a revolutionary, new-generation blood thinner. It reportedly became a billion dollar product for the manufacturer, and was popular, as it could provide those in need of blood-thinning drugs with new freedoms that traditional blood thinners could not. While traditional blood thinners often required regular physician monitoring, dosage adjustments, and certain diets, Xarelto did not. It was heavily marketed and many current plaintiffs have claimed that the marketing was misleading, and that the manufacturers did not properly note the drug’s potentially dangerous and life-threatening side effects.
Plaintiffs who have submitted federally-filed Xarelto lawsuits have had their complaints transferred and consolidated to a single court in Eastern Louisiana by the U.S. Judicial Panel on Multidistrict Litigation, forming MDL No. 2592. The lawsuits are being overseen by the Honorable Judge Eldon Fallon. As the involved plaintiffs anxiously await bellwether trials scheduled for early 2017, Attorney Joseph Osborne is working to help others who have taken the drug and who feel that it has negatively impacted their health. He feels that it is important for all affected patients to explore their legal rights in the matter, as they may be entitled to significant compensation gained through legal action. To better help those wishing to learn more about their legal options, Attorney Osborne is currently offering free legal consultations to qualified parties.
To ask questions, or request additional Xarelto lawsuit information, please contact Joseph Osborne, Esq. by calling (866) 425-8902.
http://www.digitaljournal.com/pr/2909496
-
Apr 20, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on a lawsuit which was filed against Bayer AG and Janssen Pharmaceuticals (a division of corporate giant Johnson & Johnson), as well as several other defendants, in reference to the blood-thinning drug Xarelto. The plaintiff filing this complaint alleges that Xarelto caused him to suffer from an unexpected and dangerous bleeding episode.
Since its initial filing, the plaintiff’s lawsuit has been transferred and consolidated with thousands of other federally-filed Xarelto lawsuits by the U.S. Judicial Panel on Multidistrict Litigation to form MDL No. 2592. The MDL centralizes the lawsuits to a single court in Eastern Louisiana, where they are currently being presided over by The Honorable Judge Eldon E. Fallon. Judge Fallon has been working to facilitate bellwether trial preparations for the cases and has scheduled tentative bellwether trial dates for early 2017.
Among the thousands of Xarelto lawsuits which have been filed up to this point, this complaint is significant in that it involves 90-counts and a plaintiff request for $4.35 million in compensation. Court documentation indicates that the plaintiff alleges that Bayer and Janssen marketed Xarelto misleadingly to consumers as a safe and effective drug option for patients desiring to prevent strokes, and additionally that these defendants neglected to adequately warn the public of dangerous and even life-threatening bleeding side effects which he states have been linked to the drug.
In addition, the man alleges that these manufacturers were very likely aware that the drug they had produced could cause an increased risk of bleeding episodes for those taking it. Clinical studies which were conducted on Xarelto, the plaintiff indicates, also support this allegation. He claims that if the defendants were, in fact, aware of these potential dangers, they acted with negligence by failing to better protect patients with this critically important information. The plaintiff noted, “Defendants use the results of the Rocket AF study, the Record studies, and the Einstein studies to promote Xarelto in their promotional materials, including the Xarelto website, which tout the positive results of those studies. However, defendants’ promotional materials fail to similarly highlight the increased risk of gastrointestinal bleeding and bleeding that required transfusion among other serious bleeding concerns.”
As lawsuit numbers for Xarelto continue to mount and have reportedly surpassed 3,400, many involved believe that they will only continue to grow as time progresses. Attorney Joseph Osborne is, therefore, working to help others who have used Xarelto and who feel that the drug has negatively impacted their health. He encourages affected patients to use the opportunity to investigate their legal rights in the matter fully, as they may be entitled to substantial compensation. To better assist those wanting to further explore their legal rights, Attorney Osborne is currently offering free legal consultations to qualified parties.
To request additional Xarelto lawsuit information, or to ask questions at any time, please contact Attorney Osborne by calling (866) 425-8902.
http://www.digitaljournal.com/pr/2909968
-
Apr 20, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on a lawsuit which was filed against Bayer AG and Janssen Pharmaceuticals (a division of corporate giant Johnson & Johnson), as well as several other defendants, in reference to the blood-thinning drug Xarelto. The plaintiff filing this complaint alleges that Xarelto caused him to suffer from an unexpected and dangerous bleeding episode.
Since its initial filing, the plaintiff’s lawsuit has been transferred and consolidated with thousands of other federally-filed Xarelto lawsuits by the U.S. Judicial Panel on Multidistrict Litigation to form MDL No. 2592. The MDL centralizes the lawsuits to a single court in Eastern Louisiana, where they are currently being presided over by The Honorable Judge Eldon E. Fallon. Judge Fallon has been working to facilitate bellwether trial preparations for the cases and has scheduled tentative bellwether trial dates for early 2017.
Among the thousands of Xarelto lawsuits which have been filed up to this point, this complaint is significant in that it involves 90-counts and a plaintiff request for $4.35 million in compensation. Court documentation indicates that the plaintiff alleges that Bayer and Janssen marketed Xarelto misleadingly to consumers as a safe and effective drug option for patients desiring to prevent strokes, and additionally that these defendants neglected to adequately warn the public of dangerous and even life-threatening bleeding side effects which he states have been linked to the drug.
In addition, the man alleges that these manufacturers were very likely aware that the drug they had produced could cause an increased risk of bleeding episodes for those taking it. Clinical studies which were conducted on Xarelto, the plaintiff indicates, also support this allegation. He claims that if the defendants were, in fact, aware of these potential dangers, they acted with negligence by failing to better protect patients with this critically important information. The plaintiff noted, “Defendants use the results of the Rocket AF study, the Record studies, and the Einstein studies to promote Xarelto in their promotional materials, including the Xarelto website, which tout the positive results of those studies. However, defendants’ promotional materials fail to similarly highlight the increased risk of gastrointestinal bleeding and bleeding that required transfusion among other serious bleeding concerns.”
As lawsuit numbers for Xarelto continue to mount and have reportedly surpassed 3,400, many involved believe that they will only continue to grow as time progresses. Attorney Joseph Osborne is, therefore, working to help others who have used Xarelto and who feel that the drug has negatively impacted their health. He encourages affected patients to use the opportunity to investigate their legal rights in the matter fully, as they may be entitled to substantial compensation. To better assist those wanting to further explore their legal rights, Attorney Osborne is currently offering free legal consultations to qualified parties.
To request additional Xarelto lawsuit information, or to ask questions at any time, please contact Attorney Osborne by calling (866) 425-8902.
http://www.kltv.com/story/31778358/xarelto-lawsuit-plaintiff-requests-435-million-compensation-after-suffering-alleged-uncontrollable-bleeding-episode
-
Combined Xarelto Lawsuit Numbers Surpass 3,400 In Louisiana MDL And Philadelphia Mass Tort Program
Apr 20, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on recently reported Xarelto lawsuit numbers, which show that complaints filed in reference to Xarelto against defendants Bayer AG and Janssen Pharmaceuticals (a division of Johnson & Johnson) have now surpassed 3,400 in number across the United States. This mounting number is made up of two main large groupings of lawsuits: a consolidation of over 2,800 Xarelto lawsuits which were transferred to a single court in Eastern Louisiana by the U.S. Judicial Panel on Multidistrict Litigation, forming MDL number 2592, as well as a mass tort program made up of over 620 lawsuits which was consolidated in Philadelphia, Pennsylvania by the Court of Common Pleas.
The thousands of plaintiffs involved in these lawsuits share strikingly similar claims that Janssen and Bayer have neglected to adequately warn the public and doctors about the dangerous possibility that the drug can put users at increased risk for the development of sudden and severe bleeding episodes.
Those involved are currently awaiting bellwether trial dates set for early 2017. They have received support in their allegations from the results of multiple tests which have been conducted on the drug. After only 5 years on the market, Xarelto lawsuit numbers seem to be following in the same footsteps of those that recently mounted referencing Pradaxa, a similar blood-thinning drug.
In 2011, Xarelto was given approval by the United States Food and Drug Administration (FDA) and it was initially thought of by the public as a revolutionary new type of blood thinner, as it was able to provide consumers with increased freedoms that traditional blood thinners had been unable to in the past. The drug was approved to treat patients recovering from hip or knee replacement surgeries, as well as those who were suffering from pulmonary embolism, and deep vein thrombosis. The approved uses were later expanded to treatment for patients with atrial fibrillation as well.
Many who are involved in the pending Xarelto lawsuits believe that complaint numbers will only continue to grow as time moves on and trial dates closely approach. At this time, Attorney Joseph Osborne is working to assist other patients who believe that they have also been negatively impacted by Xarelto. He wants to ensure that all patients who feel they have been affected will be provided with the opportunity to explore their legal rights in full. These patients may be entitled to substantial compensation gained through legal action. To better assist those wanting to further explore their options, Attorney Osborne is now offering complimentary legal consultations for qualified individuals.
To request further information on Xarelto bleeding lawsuits, or to ask questions, please contact Joseph Osborne, Esq. by calling (866) 425-8902.
http://www.digitaljournal.com/pr/2910070
-
Xarelto Lawsuit Numbers Surpass 3,400 Filings In Louisiana And Pennsylvania Within 5 Years
Apr 21, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on Xarelto lawsuit filings which have surpassed 3,400 in number over the last 5 years alone. Xarelto is a new-generation anticoagulant which gained approval from the U.S. Food and Drug Administration in 2011. When the anticoagulant was first released to market, it was very popular and has reportedly brought in billions of dollars for manufacturers Bayer AG and Janssen Pharmaceuticals (a division of Johnson & Johnson). The blood thinner was FDA approved to treat patients who were recovering from knee and hip replacement surgeries, as well as those suffering from deep vein thrombosis, pulmonary embolism, or atrial fibrillation by preventing the risk of blood clots and strokes.
Today, Xarelto’s popularity is somewhat changing, as many have come to consider the blood thinner to be significantly dangerous. Over 3,400 lawsuits have been filed regarding the drug by plaintiffs from across the country who share notably similar claims that use of Xarelto puts patients at increased risk for the development of sudden and dangerous bleeding episodes. Some of these episodes, several plaintiffs state, have proven deadly for their loved ones.
The lawsuit filings continue to increase in number and have been transferred and consolidated to a single court in Eastern Louisiana. Federally-filed cases from across the U.S. can be found in Eastern Louisiana thanks to the U.S. Judicial Panel on Multidistrict Litigation. This consolidation formed Multidistrict Litigation No. 2592, which is currently being presided over by the Honorable Judge Eldon Fallon. MDL complaints reportedly number over 2,800 at this time, and are joined by another grouping of over 620 other Xarelto lawsuits which have been consolidated in Philadelphia, Pennsylvania by the Court of Common Pleas to form a mass tort program.
Plaintiffs involved in the lawsuits are anxiously awaiting their trial dates, and Attorney Joseph Osborne is working to help ensure that other patients who have used Xarelto and who feel that it has negatively impacted their health will be given the opportunity to evaluate their legal rights in full. He indicates that affected parties could be entitled to substantial compensation. To better assist those patients interested in further exploring their legal options, Attorney Osborne is now offering complimentary legal consultations for affected parties.
To ask questions, or to request additional Xarelto bleeding lawsuit information, please contact Attorney Osborne by calling (866) 425-8902.
http://www.digitaljournal.com/pr/2911980
-
Apr 21, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
BloodThinnerHelp.com comments on details of an investigation which is reportedly being conducted by European regulators in reference to clinical trial results conducted on Xarelto. The investigation is coming at a time when a surge of Xarelto-related lawsuits have been filed against Bayer AG and Janssen Pharmaceuticals (a division of Johnson & Johnson). Thousands of lawsuits have been filed against the blood-thinning drug by plaintiffs who similarly allege that use of the drug can place patients at heightened risk for sudden, dangerous bleeding episodes.
The clinical trial which is reportedly under investigation was conducted by researchers at the Duke Institute for Clinical Research. Details provided in the Project On Government Oversight (POGO) seem to indicate that the official issuing the 2011 FDA approval of Xarelto had expressed concerns over the safety of the anticoagulant, and that the approval was also met with some strong contention from members of the agency.
POGO stated, “The FDA approved Xarelto in 2011 over the objections of the primary FDA scientists assigned to study its safety and effectiveness. The report by the reviewers argued that patients could be ‘at greater risk of harm from stroke and/or bleeding’ if they took Xarelto than if they were treated skillfully with Warfarin, a blood thinner that has been on the market since the 1950’s.”
In reference to the possible objections, POGO also noted, “The official who issued the FDA’s decision to approve the drug expressed a series of misgivings about it.” It was reported that this official, named as FDA Deputy Division Director Stephen M. Grant,discussed the decision to approve Xarelto and several of his concerns, noting in a November 2011 memo, “The decision was made difficult by the limitations in the design and conduct” (during the clinical trial).
Since gaining this 2011 approval from the FDA, Xarelto has also been issued two ‘black box’ warnings from the organization. These are the most severe product warnings possible to be given before a product is instead fully removed from the market for public sale. The drug has also become the topic of more than 3,400 lawsuits filed by plaintiffs from across the country.
AllGov.org discussed Xarelto clinical trial controversies further by noting, “The clinical trial relied on blood testing devices that were the subject of two FDA warning letters before the trial began and an FDA recall notice after the trial ended, according to the Project on Government Oversight (POGO). Certain devices in the INRatio product line, the warning notice read, could deliver false test results and that use of those devices may ‘cause severe or life-threatening injuries, including death’.”
It was additionally noted that at this time, the EMA, “is currently investigating whether the data generated from the INRatio device could have had any impact on the trial results and the extent of this impact, if applicable.” Those closely involved understandably are anxiously awaiting more answers as time goes on.
Attorney Joseph Osborne is working to help others who have used Xarelto and who believe that the drug caused them to experience adverse health events. Affected patients may be entitled to significant compensation, and are encouraged to take the opportunity to explore their legal rights in the matter fully. To better assist those wishing to learn more about their rights, Attorney Osborne is offering free legal consultations for qualified individuals at this time.
To request further information on Xarelto bleeding lawsuits, or to ask questions, please contact Joseph Osborne, Esq. by calling (866) 425-8902.
http://www.tristateupdate.com/story/31768084/xarelto-lawsuit-plaintiffs-await-results-from-investigation-of-european-regulators-into-xarelto-clinical-trials
-
Xarelto Lawsuit Allegations Question Anticoagulants Rare One-Pill-Per-Day Dosage
Apr 22, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on the details of one of the thousands of lawsuits which has been filed against Xarelto manufacturers Janssen Pharmaceuticals (a subdivision of Johnson & Johnson) and Bayer AG. This lawsuit is especially notable as its allegations differ from most of the rest. It was filed in a Pennsylvania State Court. Most of the thousands of Xarelto lawsuit complaints that currently exist were filed against the same defendants but instead referenced the anticoagulant’s alleged sudden bleeding episode dangers. However, this lawsuit brings up another concern: the drug’s one-pill-per-day, one-dose-for-all instructions.
Out of many blood thinners, Xarelto is the only one to offer a single pill dose. Most blood-thinning drugs instruct that users take 2 pills each day to properly ensure they will remain medicated for a full 24-hours. This plaintiff’s lawsuit indicates that this recommended once-daily dosage is ineffective in protecting patients for a full day. The plaintiff alleged this after unexpectedly suffering from a stroke just four days after beginning to use Xarelto in order to prevent strokes, which he was deemed to be at heightened risk for due to a heart condition called atrial fibrillation.
Atrial fibrillation is a fairly common heart condition which can cause patient’s heart rates to be faster than normal. This can put patients at increased risk of stroke, and therefore, patients with this condition have been approved for treatment with blood thinners. After suffering a stroke, the plaintiff filed his lawsuit in Pennsylvania on October 8, 2015. As the first lawsuit of its kind, his allegations have drawn increased public attention and have raised new concerns regarding use of the drug. In addition to claiming that the blood thinner failed to prevent his stroke, the plaintiff has alleged that the drug may have actually caused it.
After approval by the U.S. Food and Drug Administration in 2011, Xarelto was released to the market for public sale and thought of as a revolutionary, new-generation blood thinner. It reportedly became a billion dollar product for the manufacturer, and was popular, as it could provide those in need of blood-thinning drugs with new freedoms that traditional blood thinners could not. While traditional blood thinners often required regular physician monitoring, dosage adjustments, and certain diets, Xarelto did not. It was heavily marketed and many current plaintiffs have claimed that the marketing was misleading, and that the manufacturers did not properly note the drug’s potentially dangerous and life-threatening side effects.
Plaintiffs who have submitted federally-filed Xarelto lawsuits have had their complaints transferred and consolidated to a single court in Eastern Louisiana by the U.S. Judicial Panel on Multidistrict Litigation, forming MDL No. 2592. The lawsuits are being overseen by the Honorable Judge Eldon Fallon. As the involved plaintiffs anxiously await bellwether trials scheduled for early 2017, Attorney Joseph Osborne is working to help others who have taken the drug and who feel that it has negatively impacted their health. He feels that it is important for all affected patients to explore their legal rights in the matter, as they may be entitled to significant compensation gained through legal action. To better help those wishing to learn more about their legal options, Attorney Osborne is currently offering free legal consultations to qualified parties.
To ask questions, or request additional Xarelto lawsuit information, please contact Joseph Osborne, Esq. by calling (866) 425-8902.
http://www.wrcbtv.com/story/31778361/xarelto-lawsuit-allegations-question-anticoagulants-rare-one-pill-per-day-dosage
-
Xarelto Lawsuit Filings Reportedly Increasing In United States And Canada
Apr 22, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on Xarelto bleeding lawsuits, which have been steadily increasing in number in the United States, and in Canada as well. It was reported that a Xarelto related lawsuit was filed last February in Calgary, Canada and that another is expected to be filed in Ontario. To involved plaintiffs in the United States, this is proof that Canadian patients have struggled with bleeding risks and the lack of a ready antidote while using the drug as well.
On February 13th of 2015, the Calgary Sun reported that the lead plaintiff in the Canadian class action lawsuit from Calgary had come dangerously close to suffering from a heart attack after she suddenly experienced an internal bleeding episode while taking Xarelto. The woman’s lawsuit claim indicates, “The health care professionals who were treating [her] for this hemorrhaging had considerable difficulty in stopping her bleeding.” And also, “They advised her that Xarelto was the cause of her hemorrhaging and that, unlike other anticoagulants such as warfarin, there was no way to reverse the anticoagulant effects of Xarelto.”
For several years, Xarelto was released to the market with no available antidote. During this time, Xarelto patients who became hurt with even minor injuries often suffered significant bleeding. Without an antidote, it was extremely difficult for doctors to reverse the effects of the blood-thinning drug and clot the blood of patients who were bleeding. Traditional blood thinners did not have the same issue, as they were released to the market with an available antidote in vitamin K. If a patient taking a traditional blood thinner became injured and was bleeding, this allowed doctors the option of treating that patient with vitamin K to reverse the drug’s effects and clot their blood.
In America, adverse event reports surrounding Xarelto have mounted, and it was also reported that as of last February, Health Canada (the FDA’s Canadian equivalent) had been in receipt of around 1,100 reports of adverse events relating to use of the drug. The Xarelto class action lawsuit refers to this in further detail, noting, “A dozen of those adverse events registered with Health Canada indicated that death had resulted from Xarelto.”
The expected lawsuit from Ontario, in fact, involves wrongful death. Attorneys involved closely with the current Canadian class action indicated that they had expected a lawsuit to be filed on behalf of an 83 year old woman from Ontario who allegedly bled to death in November of 2013 while in the shower.
In the United States, Xarelto was approved in 2011 by the FDA and spent several years on the market without a readily available antidote for those using it. The drug is also the recipient of two “black box” warnings from the agency, which are the most severe product warnings a drug is able to receive before being removed from the market for public sale.
Plaintiffs in both Canada and the United States appear to unanimously claim that if they had been better made aware of the dangers that they now associate with use of Xarelto, they would have chosen an alternative blood-thinning treatment.
Attorneys in both the U.S. and Canada expect Xarelto lawsuit numbers to continue to increase as time progresses. In the meantime, Attorney Joseph Osborne is currently helping others in the United States who have used Xarelto and who feel that the drug has impacted their health negatively. Patients who have been affected may be entitled to significant compensation gained through legal action, so it is important that those involved take the opportunity to fully explore their legal rights in the matter. To better assist patients in doing this, Attorney Osborne is currently offering free legal consultations to qualified parties.
To request additional information on Xarelto bleeding lawsuits or to ask questions, please contact Attorney Joseph Osborne by calling (866) 425-8902.
http://www.12newsnow.com/story/31789412/xarelto-lawsuit-filings-reportedly-increasing-in-united-states-and-canada
-
Nebraska Xarelto Lawsuit Plaintiffs Allege Drug Caused Serious And Permanent Damage
Apr 21, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on another lawsuit which has been filed against Janssen Pharmaceuticals (a division of Johnson & Johnson) and manufacturer of new-generation blood thinner Xarelto. This particular complaint was filed in Eastern Louisiana under case number 2:15-cv-06514. It was filed by a couple from Nebraska who allege that Janssen marketed a dangerous blood thinner which caused the husband certain serious and lasting side effects including internal bleeding events and a decreased life expectancy.
It was reported that the husband was prescribed Xarelto and used it May 2013 through December 2013. In December, he suffered from a sudden gastrointestinal bleeding episode. The plaintiffs allege that this event was caused by Xarelto, and are requesting compensatory and punitive damages at this time.
Many plaintiffs from across the United States have stepped forward alleging much the same. Xarelto has in fact become the subject of over 3,400 lawsuits filed within the last 5 years alone, by plaintiffs who commonly claim that the anticoagulant places users at heightened risk for a variety of negative side effects, but most commonly bleeding events. Lawsuits which have been federally-filed were transferred and consolidated to a single court in Eastern Louisiana by the U.S. Judicial Panel on Multidistrict Litigation, forming MDL No. 2592. These complaints currently number over 2,800, and are joined by over 620 others in Philadelphia, Pennsylvania which were formed into a mass tort program by the Court of Common Pleas.
Plaintiffs involved in these lawsuit groupings are anxiously awaiting trial dates as new controversies surrounding the clinical trials of Xarelto and FDA approval of the drug have surfaced. Attorney Joseph Osborne believes that other lawsuits will continue to be filed in the meantime, and is currently working to help other patients who have taken Xarelto and who have suffered from adverse health events that they believe were caused by the blood thinner. Affected patients may be entitled to substantial compensation, and deserve the opportunity to explore their legal rights in the matter fully. To better assist those interested in learning more about their options, Attorney Osborne is currently offering free legal consultations to qualified individuals.
To request further Xarelto lawsuit information, or to ask questions, please contact Joseph Osborne, Esq. by calling (866) 425-8902.
http://www.abc6.com/story/31768740/nebraska-xarelto-lawsuit-plaintiffs-allege-drug-caused-serious-and-permanent-damage
-
Apr 17, 2016 | NastLaw LLC
XARELTOXarelto is a widely prescribed blood thinning medication that can cause serious and irreversible bleeding. Xarelto has been linked to numerous deaths since it was approved in 2011.
Individuals who were taking Xarelto and were hospitalized due to severe bleeding may be eligible for a lawsuit against the manufacturers of Xarelto.
WHAT IS XARELTO?
Xarelto (rivaroxaban) is a prescription medicine that acts as an anticoagulant (blood thinner) to prevent the formation of blood clots. Xarelto is manufactured by Bayer Pharmaceuticals and marketed by Janssen Pharmaceuticals.
Xarelto is used to treat deep vein thrombosis (DVT), a type of blood clot that can occur after certain types of surgery. DVT can lead to blood clots in other areas, including the lungs. Xarelto is also used to lower the risk of stroke from blood clots in people with atrial fibrillation.
Our Xarelto Lawyers have reviewed hundreds of potential lawsuits involving severe bleeding from Xarelto. If you or a loved one was taking Xarelto and was hospitalized due to serious bleeding, we may be able to help you receive financial compensation for your injuries and medical expenses. If you have any questions about Xarelto Lawsuits, contact us today for a free consultation.
XARELTO LAWSUITS
Lawsuits are being filed across the country for injuries and deaths from Xarelto. The lawsuits allege that the manufacturers of Xarelto did not provide adequate warning about the potential for serious bleeding, and did not require blood tests that would help to identify patients at a higher risk for serious bleeding.
Other allegations against Xarelto’s manufacturers include:The manufacturers of Xarelto used aggressive and expensive advertising campaigns claiming that Xarelto was superior to Warfarin, despite the higher rate of bleeding in patients taking XareltoPatients and doctors were not properly warned about the serious and life threatening risk of bleeding associated with Xarelto, and not advised how to stop bleeding when it occursDespite the numerous adverse events, injuries and deaths from Xarelto, the manufacturers continue to aggressively advertise the drug to increase their profits
XARELTO LAWYERS
Our lawyers are helping to lead the fight against Xarelto and have been appointed by the court to lead the litigation at the state and national level. Your legal team at NastLaw combines over 90 years of legal experience representing people injured by dangerous drugs like Xarelto.
We work on a contingency fee basis, meaning that we will never charge you any legal fees unless we win you compensation for your injuries. If we are successful and obtain you a settlement or verdict in your favor, our fees are a percentage of that amount. You will never have to pay any out of pocket costs for our legal services. If we don’t win your case, you don’t owe us anything.
Our dangerous lawyers have helped our clients recover billions of dollars in damages for injuries from dangerous drugs. If we file a Xarelto lawsuit on your behalf, we will attempt to recover compensation for your medical bills, pain, and other expenses as a result of:Various injuriesSerious physical pain and sufferingMedical, hospital and surgical expensesLoss of consortium and/or death
If you or a loved one was hospitalized due to bleeding while taking Xarelto, we will offer you a free lawsuit evaluation from one of our experienced Xarelto Lawyers.
http://nastlaw.com/xarelto/
-
Xarelto uncontrolled bleeding trigger lawsuits
Apr 20, 2016 | The Legal Examiner
By Shezad Malik
Lawsuits filed against the makers of Xarelto have surpassed 4,500 since the drug was approved by the U.S. Food and Drug Administration (FDA) in 2011.
Xarelto was approved by FDA for patients recovering from knee and hip replacement surgeries, as well as patients who are at a greater risk of stroke due to atrial fibrillation, and those suffering from deep vein thrombosis or pulmonary embolism. The drug was suppose to be a game-changing new type of blood thinner that could provide patients receiving the drug new freedoms not available with other blood thinners.
Lawsuits filed against the makers of Xarelto allege that the drug causes uncontrolled and/or excessive bleeding.
In one such case, the plaintiff is requesting for $4.35 million settlement. The plaintiff claims that the anticoagulant drug caused him to experience an uncontrolled and sudden bleeding episode.
This lawsuit is significant because it involves 90-counts and requests a large compensation. According to documents from the lawsuit, the plaintiff argues that the makers of Xarelto used misleading tactics to market the blood thinner as a safe and effective medication for people seeking to reduce their stroke risk. Furthermore, the plaintiff argues that the makers of Xarelto failed to sufficiently warn consumers of possible fatal side effects that the plaintiff believes can be caused by the drug.
The plaintiff argues the makers of Xarelto may have been aware that he drug could cause an increased risk of sudden bleeding episodes among patients taking the blood thinner. The plaintiff points to clinical studies conducted on Xarelto to support his argument.
Bellwether trials are expected to start February 2017. However, if you or a person you know suffered from injuries caused by Xarelto, don’t hesitate to reach out to us. Our office handles Xarelto cases across the United States.
http://fortworth.legalexaminer.com/fda-prescription-drugs/xarelto-uncontrolled-bleeding-trigger-lawsuits/
-
| Heygood, Orr & Pearson
Thousands of lawsuits have been filed by patients who suffered severe bleeding linked to the bloodthinner Xarelto. Hundreds of deaths and thousands of cases of severe bleeding incidents or other adverse events have been reported by patients who were prescribed Xarelto to prevent blood clots.
Xarelto (rivaroxaban) is an anticoagulant medication approved by the Food and Drug Administration in 2011. The drug is sold in the U.S. by Janssen, a division of Johnson & Johnson.
Xarelto is used to treat or prevent blood clots in patients at risk of deep vein thrombosis (DVT), pulmonary embolism (PE), or similar conditions. Xarelto is often prescribed to patients who have recently undergone hip or knee replacement surgery in order to prevent the formation of blood clots during the recovery period following surgery when patients are unable to walk.Xarelto Linked to Severe Bleeding Incidents
Xarelto was intended to be an alternative to the anticoagulant warfarin (Coumadin), a drug that had been the standard medication for the treatment and prevention of blood clots for decades, but which required extensive blood monitoring and dietary changes for patient safety. Janssen marketed Xarelto to patients as a safer and more convenient alternative to warfarin.
Unlike warfarin, however, Xarelto did not have an antidote that could be administered to patients in the event of severe bleeding incidents which occurred while they were being treated with the drug. These antidotes—such as the Vitamin K used for patients who suffer severe bleeding while taking warfarin—are used to immediately counter the anticoagulant effects of the drug to stop bleeding incidents before they cause severe injury or death to the patient.
Because Xarelto lacked a readily available antidote, patients who suffered injuries while taking the drug, even minor ones, could be at risk of severe and potentially fatal bleeding incidents. Xarelto users who fall down the stairs, are involved in a car accident, or suffer other non-fatal injuries may be at risk of potentially life-threatening bleeding because they are taking Xarelto. Patients who take Xarelto may also face an increased risk of gastrointestinal bleeding, epidural or spinal hematomas (spinal bleeding), hemorrhage, internal bleeding, or other types of severe bleeding incidents.
Lawsuits Filed Over Severe Bleeding Linked to Xarelto
The first Xarelto lawsuit was filed in 2014 by a patient who was hospitalized due to severe bleeding after being prescribed the drug. Since then, about 5,000 lawsuits have been filed against Janssen and Johnson & Johnson on behalf of patients who suffered severe bleeding incidents while being treated with Xarelto. The lawsuits allege that Xarelto has caused hundreds of deaths as well as thousands of other serious bleeding incidents.
Plaintiffs who have filed Xarelto lawsuits against Janssen and Johnson & Johnson say that the companies should have known about the risk of severe bleeding incidents that could be caused by the drug. The lawsuits allege that the companies failed to properly warn doctors and patients about the risk of potentially fatal bleeding that could occur with patients taking Xarelto.
Most of these Xarelto lawsuits have been consolidated in a federal multidistrict litigation (MDL) in Louisiana. The first bellwether lawsuit in the Louisiana Xarelto litigation is scheduled to go to trial in early 2017. Several hundred cases filed against Janssen are also being handled in Pennsylvania state court as part of a mass torts litigation.
Pharmaceutical Liability Lawsuits Filed by HO&P
Patients who suffered severe bleeding or other serious adverse events caused by Xarelto may be eligible to file a lawsuit. Families whose loved ones suffered fatal bleeding while taking Xarelto may also qualify to take legal action on their behalf. The first step in filing a lawsuit is to review your case with an attorney who has the knowledge and experience with pharmaceutical and product liability cases to handle your case all the way from start to finish.
At Heygood, Orr & Pearson, we believe that when drug companies put the health and safety of patients at risk in the interest of profits, they should be held accountable for their negligence in a court of law. Our lawyers have spent years holding drug and medical device manufacturers responsible for the injuries and deaths caused by their dangerous products. Our attorneys have taken on some of the largest pharmaceutical companies in the world, including cases involving drugs such as the fentanyl pain patch, Yaz, Actos, Avandia, and Accutane.
Heygood, Orr & Pearson has the financial resources to handle even the most complex pharmaceutical liability cases from beginning to end. In many instances, our law firm has invested hundreds of thousands of dollars in a case in order to take it to trial on behalf of our clients. Our attorneys are committed to achieving justice for our clients, whatever the cost.
If you or a loved one were injured as a result of severe bleeding caused by Xarelto, contact the lawyers at Heygood, Orr & Pearson for a free legal consultation about your case. You can reach us by calling toll-free at 1-877-446-9001, or by following the link to our free case evaluation form and answering a few simple questions about your case to get started.
https://www.hop-law.com/xarelto/
-
Xarelto MDL Lawsuits Top 4,500 Cases Involving Bleeding Injuries
Apr 20, 2016 | AboutLawsuits.com
By Joseph Osborne
As parties involved in the federal Xarelto bleeding injury lawsuits are scheduled to meet today with the judge presiding over the coordinated pretrial proceedings, a new report suggests that the total number of cases pending in the federal multidistrict litigation (MDL) has recently topped 4,500.
Since December 2014, all product liability lawsuits filed in U.S. District Courts nationwide over the bleeding side effects of Xarelto have been centralized for discovery and a series of early bellwether trials, which are designed to help gauge how juries may respond to certain evidence and testimony that is likely to be repeated throughout a large number of claims.
The MDL is consolidated before U.S. District Judge Eldon Fallon in the Eastern District of Louisiana to reduce duplicative discovery into common issues that will arise in the cases, avoid conflicting pretrial rulings from different courts and to serve the convenience of the parties, witnesses and the courts.
According to a case list (PDF) released by the U.S. Judicial Panel on Multidistrict Litigation (JPML) on April 15, there are currently at least 4,579 Xarelto MDL lawsuits pending before Judge Fallon, each involving similar allegations that the the makers of the novel oral anticoagulant failed to adequately warn users and the medical community about the risk of uncontrollable bleeds.
In a joint status report (PDF) submitted on Monday, the parties outlined several issues that will be discussed with Judge Fallon during tomorrow’s case management conference, including issues surrounding discovery, depositions, preservation of certain data and the status of coordination efforts between the MDL and similar cases pending at the state court level.Xarelto Bleeding Problems
Xarelto (rivaroxoaban) is a new-generation anticoagulant that was introduced in 2011 as a replacement for Coumadin (warfarin), which has been the go-to anticoagulant treatment for decades.
The drug is part of a new class of medications designed to avoid blood clots among individuals at risk for deep vein thrombosis or pulmonary embolism, which have been promoted as easier to use than warfarin. However, since the drugs have hit the market, there have been a large number of reports involving severe and sometimes fatal bleeding problems with Xarelto and other members of this new class, including Pradaxa and Eliquis.
Each of the lawsuits involved in the Xarelto MDL raise nearly identical allegations, indicating that the drug carries a high risk of severe bleeds, and that information was withheld from the medical community about the lack of a safe and effective reversal agent for Xarleto to allow doctors to quickly stop the blood thinning effects of the drug.
While all blood thinners carry a risk of bleeding injury, the side effects of warfarin can be quickly reversed with a widely known antidote of bleeding occurs. However, there was no Xarelto reversal agent when the drug was introduced. Plaintiffs allege that the drug makers failed to adequately warn doctors about the lack of an antidote.
Similar claims were raised in the litigation over Pradaxa, which is a different medication that is part of the same new class of novel oral anticoagulants.
More than 4,000 Pradaxa lawsuits were ultimately filed by users of that drug who suffered bleeding injuries over that medication, which was introduced about one year before Xarelto.
Following several years of litigation, the manufacturer of that medication ultimately agreed to pay $650 million in Pradaxa settlements, with an average of about $150,000 per claim.
As Xarelto injury lawyers continue to review potential cases for individuals and families nationwide, it is expected that the number of lawsuits involved in the MDL will continue to grow over the coming months, and will far exceed those involved in the Pradaxa litigation.
Judge Fallon has scheduled a series of early Xarleto bellwether trials in the MDL, which are expected to begin in February 2017. While the outcomes of these early trial dates will not be binding on other claims, they may help the parties negotiate Xarelto settlements that could avoid the need for thousands of individual cases to go before juries nationwide.
http://www.aboutlawsuits.com/4500-xarelto-lawsuits-filed-99229/
-
Canadian Xarelto Class Action Lawsuit Filed
Apr 21, 2016 | BigClassAction.com
Bayer Inc, is facing a Xarelto class-action lawsuit filed in Calgary alleging its blood thinner is linked to dozens of deaths. The lead plaintiff in this class action alleges that the anticoagulant drug caused her to suffer from an uncontrollable bleeding event which nearly led her to cardiac arrest.
According to reports published in the Calgary Sun, as of March 2015, Health Canada had received an estimated 1,100 adverse event reports from patients taking Xarelto. The article indicates that, according to a lawyer from Toronto, if the class action is successful, “...it would be in the millions of dollars.” The Calgary Sun report also discussed the likely formation of another class action suit in Ontario at this time.
Xarelto (known generically as Rivaroxaban) is a new-generation anticoagulant, in a class of drugs known as direct thrombin inhibitors. It is a blood thinner used to reduce the risk of blood clots and strokes. Xarelto has also been marketed as being easier to use than warfarin (known by the brand name Coumadin), an older anticoagulant, because it does not require medical monitoring.
Xarelto has reportedly been linked to an increased risk of uncontrollable bleeding (hemorrhaging). A risk of hemorrhaging exists in many blood thinners; however, warfarin has an antidote in that can reduce the risk of uncontrollable hemorrhaging. Some newer blood thinners do not have an antidote. This means that injuries, including minor cuts or internal bleeding, can result in uncontrolled bleeding, which can be fatal.
This Canadian class action lawsuit closely follows the formation of Multidistrict Litigation number 2592 in the United States by the U.S. Judicial Panel on Multidistrict Litigation. This MDL consolidated and transferred over 2,800 lawsuits filed in reference to Xarelto by plaintiffs who allege much the same. These lawsuits are additionally joined by another group of 620 Xarelto lawsuits which have been formed into a mass tort program by the Court of Common Pleas in Philadelphia, Pennsylvania. Lawsuits in these groupings have been filed against defendant Bayer AG as well as Janssen Pharmaceuticals, a subdivision of Johnson & Johnson corporation.
In the US, the FDA has given the blood thinner two “black box” warnings, which are the severest warnings a product can receive before it is removed from the market for public sale.
The plaintiff in the Canadian Xarelto class action is represented by Toronto lawyer Bryan McPhadden.https://www.bigclassaction.com/lawsuit/canadian-xarelto-class-action-lawsuit-side-effects.php
-
Court Chooses 40 Xarelto Lawsuits for Bellwether Trial
Apr 21, 2016 | Top Class Actions
By Joanna Szabo
All federally filed Xarelto lawsuits were consolidated into one multidistrict litigation, or MDL, on Dec. 12, 2014 in the Eastern District of Louisiana, and potential cases for early bellwether trials have been reviewed since the MDL consolidation.
The judge overseeing the proceedings, Judge Eldon E. Fallon, confirmed on March 7 that 40 Xarelto lawsuits have been selected for the bellwether trial discovery pool. Others Xarelto lawsuits have been scheduled for case-specific depositions to be held over the next few months.
The Xarelto lawsuits from the discovery pool will help both parties to gather evidence that can be used during bellwether trials. Bellwether trials use just a few Xarelto lawsuits to gauge how juries respond to the evidence.
Because these Xarelto lawsuits have been consolidated and have generally been found to be similar, the results of bellwether trials are usually repeated throughout all of the litigation. Bellwether trials, therefore, help to more quickly and efficiently determine the results of litigation.
Sometimes, particularly strong bellwether trials can encourage parties to seek a settlement rather than to continue litigation.
The first bellwether trials are scheduled for early 2017.
Xarelto Background
Xarelto (rivaroxaban) was first approved by the U.S. Food and Drug Administration in July 2011. Xarelto is an anticoagulant medication intended to prevent blood clots in patients going through hip and knee replacements. Xarelto was marketed as being superior to warfarin, the traditional staple blood thinner, because it did not require frequent blood monitoring.
Though Xarelto was initially approved to prevent blood clots for hip and knee replacement patients, it was later approved to prevent stroke and deep vein thrombosis.
Despite Xarelto’s rising popularity, it is also the subject of hundreds of adverse events reports. These reports claim that Xarelto has led to internal bleeding. In some cases, these Xarelto side effects are reportedly so severe that they led to death.
According to the Institute of Safe Medicine Practices QuarterWatch publication, Xarelto had a total of 356 cases of serious Xarelto side effects just one year after its release into the market.
Xarelto Lawsuits
The FDA has taken action, warning Xarelto manufacturers that they have released false or misleading marketing that downplays Xarelto risks. Xarelto manufacturers Janssen Pharmaceuticals and Bayer AG are facing a number of Xarelto lawsuits that claim consumers and the medical community were not adequately warned of the potentially serious Xarelto side effects.
One of the major problems with Xarelto, lawsuits claim, is that unlike warfarin, Xarelto does not have an antidote available to reverse the potentially life-threatening internal bleeding effects. Therefore, patients who are suffering from internal bleeding may end up bleeding much more excessively than they would have had they not taken Xarelto.
If you or someone you know has experienced Xarelto side effects such as Xarelto bleeding, you may be able to join a class action Xarelto bleeding lawsuit.
https://topclassactions.com/lawsuit-settlements/prescription/333233-court-chooses-40-xarelto-lawsuits-bellwether-trial/
-
Xarelto Users Scrutinize TV Ads After Suffering Injuries
Apr 21, 2016 | Meyerkord & Meyerkord LLC
Retired NBA player, Chris Bosh, comedian, Kevin Nealon, golfer, Arnold Palmer, and Nascar driver, Kevin Vickers, are all featured in several television commercials advertising the blood thinner Xarelto. In the commercials, they praise the drug and promote it as being the best choice for individuals needing a blood thinner. The main focus in the commercials is that Xarelto is the most convenient option compared to other blood thinners. Warfarin, a coagulant that has been on the market for several years, requires users to undergo regular blood tests and alter their diets. Xarelto does not require any changes to the users lifestyle. Many Xarelto users are angry after witnessing the advertisements claiming they were injured as a result of the drug.
Over 3,400 individuals have filed lawsuits against Bayer and Johnson & Johnson, the manufacturers of Xarelto, after suffering injuries or the loss of a loved one as a result of the drug’s side effects. While the manufacturers often compare Xarelto to Warfarin to promote the drug’s convenience, Bayer and J & J fail to inform users of the major difference between the drugs which is that Xarelto does not have an antidote. Warfarin users that experience an injury can be administered Vitamin K to clot the blood and reverse the effects of the drug. Xarelto users continue to experience uncontrollable bleeding when an injury occurs due to the lack of an antidote.
If you or a loved one have experienced injuries or death after taking Xarelto, it is important to consult the drug liability attorneys at Meyerkord & Meyerkord, LLC. We will work to hold any company responsible for producing an unsafe or dangerous drug. We believe that you are entitled to justice, and we will fight to obtain it. Contact the St. Louis drug liability attorneys at Meyerkord & Meyerkord, LLC today for a free no-obligation consultation.
http://www.stlouis-personalinjury.com/Blog/2016/April/Xarelto-Users-Scrutinize-TV-Ads-After-Suffering-.aspx
Client Attorney Privileged/Attorney Work Product/At Request of Counsel
Full Text of Stories Below
Plaintiff Attorney Press Releases
Plaintiff Attorney Blog Posts
Add recipients
Suggested